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Abstract
Background: Oxidative stress and inflammation are implicated in the pathogenesis of retinopathy
in diabetes. The aim of this study is to examine the effect of curcumin, a polyphenol with antioxidant
and anti-inflammatory properties, on diabetes-induced oxidative stress and inflammation in the
retina of rats.
Methods: A group of streptozotocin-induced diabetic rats received powdered diet supplemented
with 0.05% curcumin (w/w), and another group received diet without curcumin. The diets were
initiated soon after induction of diabetes, and the rats were sacrificed 6 weeks after induction of
diabetes. The retina was used to quantify oxidative stress and pro-inflammatory markers.
Results: Antioxidant capacity and the levels of intracellular antioxidant, GSH (reduced form of
glutathione) levels were decreased by about 30–35%, and oxidatively modified DNA (8-OHdG) and
nitrotyrosine were increased by 60–70% in the retina of diabetic rats. The levels of interleukin-1β
(IL-1β) and vascular endothelial growth factor (VEGF) were elevated by 30% and 110% respectively,
and the nuclear transcription factor (NF-kB) was activated by 2 fold. Curcumin administration
prevented diabetes-induced decrease in the antioxidant capacity, and increase in 8-OHdG and
nitrotyrosine; however, it had only partial beneficial effect on retinal GSH. Curcumin also inhibited
diabetes-induced elevation in the levels of IL-1β, VEGF and NF-kB. The effects of curcumin were
achieved without amelioration of the severity of hyperglycemia.
Conclusion: Thus, the beneficial effects of curcumin on the metabolic abnormalities postulated to
be important in the development of diabetic retinopathy suggest that curcumin could have potential
benefits in inhibiting the development of retinopathy in diabetic patients.
Background
Diabetic retinopathy is the main cause of acquired blind-
ness in working adults. Abnormalities in retinal metabo-
lism, including elevated polyol pathway activity,
increased nonenzymatic glycation and advanced glyca-
tion end products, oxidative stress, protein kinase C
(PKC) activity [1-5], evidently contribute to the develop-
ment of retinopathy, but the exact mechanism is still elu-
sive. In diabetes the retina experiences increased oxidative
stress [4,6-8], and reactive oxygen species (ROS) are con-
sidered as a causal link between elevated glucose and the
metabolic abnormalities important in the development of
diabetic complications [9]. However, the mechanism by
Published: 16 April 2007
Nutrition & Metabolism 2007, 4:8 doi:10.1186/1743-7075-4-8
Received: 25 January 2007
Accepted: 16 April 2007
This article is available from: http://www.nutritionandmetabolism.com/content/4/1/8
© 2007 Kowluru and Kanwar; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Nutrition & Metabolism 2007, 4:8 http://www.nutritionandmetabolism.com/content/4/1/8
Page 2 of 8
(page number not for citation purposes)
which oxidative stress can contribute to the development
of diabetic retinopathy remains to be elucidated.
Recent studies have compared the development of dia-
betic retinopathy to the low-level chronic inflammatory
disease; the retinal capillaries become nonperfused and
ischemic, and the number of platelet-fibrin thrombi
increases in diabetes [10]. The levels of pro-inflammatory
cytokines are increased in the retina and vitreous in diabe-
tes [11,12]. We have shown that intravitreal injection of
interleukin-1β (IL-1β) to the normal rats increases retinal
capillary cell apoptosis and histopathology; and these IL-
1β-induced changes in the retinal capillaries of normal
rats are similar to those observed in diabetes [13]. Further,
IL-1β is shown to increase the expression of vascular
endothelial growth factor (VEGF) in retinal endothelial
cells [14], and VEGF is implicated in the development of
diabetic retinopathy [15].
Curcumin, a bis-α, β-unsaturated β-diketone (Figure 1),
possesses diverse antioxidant and anti-inflammatory
properties [16,17]. It significantly decreases lipid peroxi-
dation, increases intracellular antioxidant, GSH, regulates
antioxidant enzymes, and scavenges hyperglycemia-
induced ROS [18,19]. In addition, curcumin is shown to
inhibit the pro-inflammatory transcriptional factor, NF-
kB, and prevent up-regulation of VEGF mRNA and micro-
vascular angiogenesis [20]. However, the beneficial effect
of curcumin on diabetic retinopathy remains to be
explored.
In the present study we have investigated the effect of
administration of curcumin on oxidative stress and
inflammatory markers in the retina of diabetes. The total
antioxidant capacity, and the levels of GSH, oxidatively
modified DNA (8-OHdG), nitrotyrosine, IL-1β, NF-kB
and VEGF were quantified in the retina of diabetic rats
that received diets supplemented with or without curcu-
min for 6 weeks, and for comparison, in the retina of age-
matched normal control rats. The results presented show
that curcumin administration for 6 weeks prevents diabe-
tes-induced increase in retinal oxidative stress and inhibits
the levels of pro-inflammatory markers.
Methods
Rats
Lewis rats (200 to 220 g, male) were made diabetic with
streptozotocin (55 mg/kg body weight). Insulin was
administered to diabetic rats to allow slow weight gain
while maintaining hyperglycemia (blood glucose levels of
20–25 mM). Age-matched normal rats served as control.
Diabetic rats were divided into 2 groups: the rats in group
1 received powdered diet (Purina 5001) without any sup-
plementation, and group 2 received diet supplemented
with curcumin (0.5 g/kg diet); these diets were initiated
soon after establishment of diabetes (3–4 days after
administration of streptozotocin). Each group had 8–12
rats, and the entire rat colony received fresh powdered diet
weekly. The rats were weighed two times a week and their
food consumption was measured once every week. After 6
weeks of diabetes the rats were euthanized by an overdose
of pentobarbital, the eyes were removed, and retina was
isolated and frozen immediately in liquid nitrogen for
biochemical measurements. Treatment of the animals
conformed to the National Institutes of Health Principles
of Laboratory Animal Care, the Association for Research
in Vision and Ophthalmology Resolution on the Use of
Animals in Research, and the Institutional guidelines.
Oxidative stress
The total antioxidant capacity of the retina was measured
using a kit from Cayman Chemical (Ann Arbor, MI)
according to the method recently used by us [21]. The
assay is based on the ability of the sample to inhibit oxi-
dation of 2,2'-Azino-di- [3-ethylbenzthiazoline sul-
fonate]+ (ABTS) by metmyoglobin; the antioxidants in the
sample cause the decrease in absorbance at 750 nm, and
that represents the amount of ABTS+ produced. Each sam-
ple was measured in duplicate.
The levels of 8-OHdG were quantified by competitive
ELISA (Oxis Research Laboratories, OR) using 15–20 μg
DNA purified from the retina that has been digested with
DNAse, as described previously [22].
GSH was measured using the Glutathione Assay Kit from
Cayman Chemical (Ann Arbor, MI) [22]. Fifteen to 25μg
retinal protein was deproteinized using phosphoric acid,
and the supernatant was used to measure the amount of
5-thio-2-nitrobenzoic acid.
Peroxynitrite is formed by the reaction between superox-
ide and nitric oxide, and nitrotyrosine is a measure of per-
oxynitrite. Nitrotyrosine levels were quantified by enzyme
immunoassay using a Nitrotyrosine-EIA kit from Oxis
Research, Portland, OR, as previously used by us [22]. The
sensitivity of the assay was as low as 0.05 pmoles of nitro-
tyrosine.
Inflammation
The amount of IL-1β was quantified in the retina by ELISA
(R&D Systems, Minneapolis, MN) as previously described
by us [12]. Unbound substances were removed by incu-
bating the samples with rat polyclonal antibody in pre-
coated microplates. The results are reported as pg of IL-1β/
mg retina protein in each sample.
VEGF levels were quantified in the retina by an ELISA
method using a kit from R&D Systems, MN. The standard
solution or the samples were added in a 96-well plate thatNutrition & Metabolism 2007, 4:8 http://www.nutritionandmetabolism.com/content/4/1/8
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was pre-coated with a monoclonal antibody. The samples
were incubated for 2 hours, and after washing the plate
the samples were incubated with rat VEGF-conjugate. The
assay was sensitive to the concentration of VEGF as low as
15 ng/ml.
The activation of the transcription factor that is under the
control of IL-1β, NF-kB, was determined by ELISA that is
based on the principle that only the active form of NF-kB
in the sample binds to oligonucleotide containing NF-kB
consensus site (5,-GGGACTTTCC-3'), which is immobi-
lized on the microtiter plate. Eight-10 μg of retina protein
was sufficient to provide reliable readings [22].
Protein expressions of IL-1β, VEGF and p65 subunit of
NF-kB were determined by western blot using polyclonal
antibodies against IL-1β, VEGF and p65 respectively. The
membranes were developed using ECL-Plus western blot-
ting reagents, and β-actin was used as a house-keeping
protein.
Statistical analysis
Data are reported as mean ± SD. The results were analyzed
using one-way ANOVA followed by Fischer's test. Similar
conclusions were reached by nonparametric Kruskal-Wal-
lis, test followed by Mann-Whitney test for multiple group
comparison.
Results
Oxidative stress
Oxidative stress, as determined by the overall antioxidant
capacity, concentration of the intracellular antioxidant
and the levels of oxidatively modified DNA remained ele-
vated in the retina of rats diabetic for 6 weeks. The antioxi-
dant capacity of the retina and GSH levels were decreased
by about 30–35% (Figure 2), and 8-OHdG levels were ele-
vated by over 70% (Figure 3) in diabetes compared to the
age-matched normal control rats.
Administration of curcumin prevented diabetes-induced
decrease in the total antioxidant capacity of the retina; the
values obtained from normal control rats and in curcu-
min-treated diabetic rats were similar (Figure 2a). How-
ever, diabetes-induced decrease in retinal GSH was
partially inhibited by curcumin administration; although
GSH levels were lower in the retina of curcumin-treated
diabetic rats compared to the normal control rats, these
values were significantly higher compared to the diabetes
group (P = 0.04; Figure 2b). In the same rats, curcumin
administration had significant beneficial effect on oxida-
tive modification of retinal DNA; 8-OHdG values in cur-
cumin-treated diabetic group and normal control group
were not different from each other (P = 0.32 compared to
normal, Figure 3).
Six weeks of diabetes increased nitrotyrosine levels in the
retina by about 60% compared to the values obtained
from normal control rats (Figure 4). Curcumin supple-
mentation in diabetic rats prevented increase in retinal
nitrotyrosine levels; the values in the curcumin-treated
diabetic rats were significantly lower compared to diabetic
rats without curcumin (P < 0.05, Figure 4).
Inflammation
The concentration of the inflammatory cytokine IL-1β
and its protein expression were elevated by 30% in the ret-
ina of diabetic rats (Figure 5). In the same retina, the tran-
scription factor that is under the control of IL-1β, NF-kB,
was also activated by about 2 fold (Figure 6). Administra-
tion of curcumin inhibited diabetes-induced increase in
inflammatory markers in the retina; the levels of IL-1β
were significantly decreased in diabetic rats receiving cur-
Structure of curcumin Figure 1
Structure of curcumin. 1,7-bis (4-hydroxy-3-methoxy-phenyl) hepta-1, 6-diene-3, 5-dione).Nutrition & Metabolism 2007, 4:8 http://www.nutritionandmetabolism.com/content/4/1/8
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cumin (P < 0.05), and in the same retina the activation of
NF-kB was also diminished.
The endothelial growth factor, VEGF, was elevated by over
2 fold in the retina obtained from diabetic rats (Figure 7).
Supplementation with curcumin prevented diabetes-
induced increase in VEGF; the values obtained from nor-
mal control and diabetes + curcumin rats were not signif-
icantly different from each other.
Similar beneficial effects of curcumin supplementation
were obtained on diabetes-induced increased protein
expression of retinal IL-1β, p65 subunit of NF-kB and
VEGF (data not shown).
Severity of hyperglycemia
The severity of hyperglycemia, as measured by body
weight of the rats and their blood glucose and 24 hour
urine volumes, was strikingly increased in the diabetes
group compared with the normal control group. Curcu-
min did not ameliorate the severity of hyperglycemia in
diabetic rats; the body weight, blood glucose and urine
volumes were comparable between the two diabetic
groups (diabetes and diabetes + curcumin), and these
parameters were significantly different (P < 0.001) from
the normal control group (Table 1). The average curcumin
consumption in diabetic rats, calculated from the daily
average food intake, was about 16 mg/day.
Discussion
This is the first report showing that curcumin, a polyphe-
nol, has beneficial effects on retinal metabolic abnormal-
ities, including oxidative stress and inflammation, which
are considered to be important in the development of
retinopathy in diabetes. These results raise the possibility
that curcumin may help inhibit the development of dia-
betic retinopathy.
The antioxidant capacity, a measure of the total protective
antioxidant mechanisms (both for preventing the produc-
tion of free radicals and for repairing oxidative damage)
[23], of curcumin has been considered to be mediated via
its beneficial effects on the antioxidant defense system,
the scavenging of free radicals and/or via preventing lipid
peroxidation and it is at least 10 times more active as an
antioxidant than vitamin E [24]. Diabetes decreases the
Effect of curcumin on diabetes-induced oxidative stress in the retina Figure 2
Effect of curcumin on diabetes-induced oxidative stress in the retina. (a) Total antioxidant capacity of the retina was 
quantified by measuring the ability of the retina to inhibit oxidation of ABTS by metmyoglobin using 5–10 μg retina protein. (b) 
Retinal GSH was estimated in the deproteinizing retinal homogenate using a kit from Cayman Chemical (MI). Each sample was 
measured in duplicate, and the values are represented as mean ± SD of 7–8 rats in diabetes group and 7–9 rats each on normal 
and diabetes + curcumin groups. Norm = normal; Diab = Diabetes; Diab + Curc = Diabetes + curcumin treated rats. *P < 0.05 
compared to normal, #P < compared to diabetes + curcumin.
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total antioxidant capacity of the retina [21], and here we
provide data showing that the administration of curcumin
can prevent diabetes-induced decrease in the total antioxi- dant capacity of the retina. This suggests that curcumin
has a potential to inhibit overall oxidative damage experi-
enced by the retina in diabetes.
Administration of curcumin decreases diabetes-induced
increase in retinal 8-OHdG levels. In support, recent stud-
ies by Farhangkhoee et al [25] have shown that curcumin
treatment decreases diabetes-induced increased 8-OHdG
immunoreactivity in the heart. 8-OHdG has been impli-
cated in the pathogenesis of diabetic retinopathy; inhibi-
tion of increased retinal capillary cell apoptosis and the
development of diabetic retinopathy by lipoic acid are
considered to be mediated via inhibition of increased ret-
inal 8-OHdG levels [25]. The role of increased retinal 8-
OHdG levels in the pathogenesis of diabetic retinopathy
is further strengthened by the studies showing that over-
expression of mitochondrial superoxide dismutase
(MnSOD) inhibits increase in retinal 8-OHdG levels
[8,21]. Inhibition of diabetes-induced elevated retinal 8-
OHdG levels by curcumin suggests that curcumin could
inhibit the development of diabetic retinopathy, in part,
via inhibiting accumulation of oxidized DNA in the ret-
ina.
GSH, an intracellular antioxidant, is important in antioxi-
dant defense, nutrient metabolism, and regulation of cel-
lular events, including gene expression, apoptosis and
Effect of curcumin on diabetes-induced increase in retinal IL- 1β levels Figure 5
Effect of curcumin on diabetes-induced increase in 
retinal IL-1β levels. An ELISA kit from R&D Systems, Min-
neapolis, MN, was used to quantify IL-1β in the retina. Each 
sample was run in duplicate to ensure reproducibility of the 
data. IL-1β values (pg IL-1β/mg protein) are mean ± SD 
obtained from 8 rats each in diabetes and diabetes + curcu-
min groups and 6 rats in normal group. *P < 0.05 and #P < 
0.05 compared to normal and diabetes + curcumin groups 
respectively.
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Effect of curcumin on oxidatively modified DNA levels in the  retina Figure 3
Effect of curcumin on oxidatively modified DNA lev-
els in the retina. 8-OHdG levels were measured in the ret-
ina using an ELISA kit from Oxis Research. Values are 
represented as mean ± SD of 6–8 rats in each group. *P < 
0.05 compared to normal, and #P < 0.05 compared to diabe-
tes + curcumin.
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Effect of curcumin on retinal nitrotyrosine levels in diabetes Figure 4
Effect of curcumin on retinal nitrotyrosine levels in 
diabetes. Nitrotyrosine-EIA kit was used to quantify nitro-
tyrosine in the retina. Each sample was measured in dupli-
cate. The figure represents mean ± SD of 6 rats each in 
normal and diabetes + curcumin groups and 7 rats in diabe-
tes group. *P < 0.05 compared to normal, #P < compared to 
diabetes + curcumin.
N
i
t
r
o
t
y
r
o
s
i
n
e
 
(
n
m
o
l
e
s
/
m
g
 
p
r
o
t
e
i
n
)
0.0
0.7
1.4
2.1
2.8
3.5
Norm Diab Diab+Curc
* #Nutrition & Metabolism 2007, 4:8 http://www.nutritionandmetabolism.com/content/4/1/8
Page 6 of 8
(page number not for citation purposes)
cytokine production [26]. Decreased GSH levels are
observed in the retina in diabetes, and antioxidants and
MnSOD overexpression inhibit such diabetes-induced
decreases in retinal GSH [22,27]. Here, we provide data
demonstrating that curcumin administration has partial
beneficial effect on diabetes-induced decrease in retinal
GSH; the GSH levels in curcumin-treated diabetic rats
remained significantly lower than those in the normal
control rats, but were significantly higher than diabetic
rats. Others have shown that curcumin administration
increases defense against oxidative stress in the liver via a
GSH-linked mechanism [28]. Our failure to achieve com-
plete restoration of retinal GSH levels could be that higher
levels of curcumin may be essential to regulate retinal
GSH metabolism in diabetes, and the rats in our experi-
ment were not able to achieve such levels. Or, there could
be compartmentalization of GSH in the retina, and levels
could possibly be normalized in the cells associated with
the development of diabetic retinopathy.
The therapies that inhibit diabetes-induced nitrotyrosine
accumulation in the retina are shown to inhibit diabetic
retinopathy [22,29,30]. Here we demonstrate that curcu-
min can prevent diabetes-induced increase in nitrotyro-
sine levels in the retina. In support, curcumin has been
reported to inhibit diabetes-induced increased nitrotyro-
sine immunostaining in the heart [25], and also is postu-
lated to exert its neuroprotective effects and prevent
alcohol-induced liver damage via regulating peroxynitrite
levels [31,32].
Diabetic retinopathy shares similarities with low level
chronic inflammatory disease, and subclinical inflamma-
tion is considered to play a role in the vascular lesions
characteristic of diabetic retinopathy [33]. The levels of
cytokines, including IL-1β, IL-6 and IL-8, are increased in
the vitreous of patients with proliferative diabetic retinop-
athy and in the retina from diabetic rats and mice
[11,22,34]. The capillaries become nonperfused and
ischemic and the number of platelet-fibrin thrombi
increases; these pro-inflammatory changes and leukosta-
sis constitute as some of the earliest changes observed in
the retina of diabetic animals [10]. ROS are considered as
strong stimuli for the release of cytokines, and IL-1β itself
can trigger signaling cascades resulting in excessive ROS
[14]. Our data demonstrate that curcumin, a compound
with both anti-inflammatory and antioxidant properties,
prevents diabetes-induced increase in IL-1β. This suggests
that curcumin could inhibit the development of diabetic
retinopathy by inhibiting both, proinflammatory
cytokines and oxidative stress.
IL-1β induces the expression of various genes whose pro-
moters are regulated through complex interactions with
NF-kB [35]. NF-kB, a redox sensitive factor and a key reg-
ulator of antioxidant enzymes, can initiate transcription
of many genes involved in apoptosis [36], and curcumin
VEGF levels in curcumin-treated rats Figure 7
VEGF levels in curcumin-treated rats. VEGF concentra-
tions were measured in the retina of rats in normal, diabetes 
and diabetes + curcumin groups using an ELISA kit from R&D 
Systems. Results are presented as mean ± SD of 6 rats in dia-
betes and 7 rats each in normal and diabetes + curcumin 
groups. *P < 0.05 compared to normal, and #P < 0.05 com-
pared to diabetes + curcumin.
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Effect of curcumin on NF-kB activation Figure 6
Effect of curcumin on NF-kB activation. NF-kB activa-
tion was determined in the retinal homogenate by ELISA 
method (kit from Active Motif.) using antibody specific for 
p65 subunit of NF-kB. Secondary antibody conjugated to 
horseradish peroxidase was used to quantify the activated 
form spectrophotometrically. The figure represents mean ± 
SD of 5–6 rats each in of the 3 groups. *P < 0.05 compared 
with normal or diabetes + curcumin groups.
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is a potent blocker of NF-kB activation [37]. We have
shown that NF-kB is activated in the retina and its capil-
lary cells in diabetes, and its activation is an early event in
the development of retinopathy that is sustained when
retinal capillary cell death is accelerating, and histopathol-
ogy is developing [29]. In the pathogenesis of diabetic
retinopathy activation of NF-kB is reported to trigger a
developing pro-apoptotic program in retinal pericytes
[38], and accelerated apoptosis can predict the develop-
ment of retinopathy in diabetes [39]. Here we provide
clear evidence that curcumin administration inhibits the
activation of NF-kB, accumulation of 8-OHdG and nitro-
tyrosine in the retina in diabetes. This raises a possibility
that curcumin can inhibit apoptosis of retinal capillary
cells, a predictor of the development of diabetic retinopa-
thy [39].
Diabetic retinopathy is accompanied by elevation in vari-
ous angiogenic factors, and VEGF, a hypoxia-induced
growth factor, is considered to play a pivotal role in the
increased permeability and angiogenesis seen in diabetic
retinopathy [15]. Oxidative stress is considered to regulate
diabetes-induced retinal VEGF levels [40]. Our data
clearly show that curcumin administration inhibits
increased VEGF levels in the retina. In agreement, others
have shown that curcumin can abolish IL-18 induced
increase in VEGF production [41].
The beneficial effects of curcumin observed in the present
study were achieved without amelioration of the severity
of hyperglycemia in diabetic rats; the blood glucose, urine
volume and body weights were similar in diabetic rats and
diabetes + curcumin rats.
Curcumin is shown to be safely tolerated, clinical trials
using up to 8000 mg curcumin per day for 3 months have
shown no toxicity to curcumin [42]. Based on the food
consumption, the rats in our experiment consumed about
16 mg curcumin per day (about 80 mg/kgBW), and this
concentration is within the range of the concentration
used for clinical trials. However, curcumin has poor oral
bioavailability [43] that could limit its full potential in the
retina. To increase its bioavailability, curcumin can be
encapsulated in liposomes [44]; and that could allow the
use of higher concentration to possibly inhibit diabetic
retinopathy. Although, due to tissue limitations, direct
measurements of curcumin levels in the retina were not
made, the beneficial effects of curcumin observed in our
study imply that curcumin was able to cross the blood-ret-
ina barrier. This is supported by others showing that cur-
cumin can cross the blood-brain barrier in mice, and
brain curcumin levels achieved are comparable to the lev-
els achieved in the plasma [45].
Conclusion
The pathogenesis of diabetic retinopathy is complex. Cur-
cumin, a common food additive, has beneficial effects in
experimental studies of the diseases that are characterized
by increased oxidative stress and inflammatory reactions
supporting its clinical use. Our studies are the first to show
that curcumin can inhibit diabetes-induced retinal abnor-
malities that are postulated in the development of dia-
betic retinopathy. Thus, curcumin appears to be a useful
adjunct therapy to possibly inhibit the development/pro-
gression of retinopathy, the sight threatening complica-
tion faced by diabetic patients.
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